Gunilla Enblad – Tumour biology and clinical studies of lymphomas and prostate cancer

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis

Ren, Weicheng; Wan, Hui; Abd Own, Sulaf; Berglund, Mattias et al.

Part of Leukemia, p. 438-441, 2024

• DOI for Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis
• Download full text (pdf) of Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis

Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors

Tarai, Sambit; Lundström, Elin; Sjöholm, Therese; Jönsson, Hanna et al.

Part of Heliyon, 2024

• DOI for Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors
• Download full text (pdf) of Improved automated tumor segmentation in whole-body 3D scans using multi-directional 2D projection-based priors

Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial

Luminari, Stefano; Fossa, Alexander; Trotman, Judith; Molin, Daniel et al.

Part of Journal of Clinical Oncology, p. 13-18, 2024

• DOI for Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial
• Download full text (pdf) of Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial

Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy

Harrysson, Sara; Eloranta, Sandra; Ekberg, Sara; Enblad, Gunilla et al.

Part of Leukemia and Lymphoma, p. 534-537, 2024

• DOI for Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy

The National Swedish Lymphoma Register - a systematic validation of data quality

Smedby, Karin E.; Eloranta, Sandra; Wasterlid, Tove; Falini, Victor et al.

Part of Acta Oncologica, p. 563-572, 2024

• DOI for The National Swedish Lymphoma Register - a systematic validation of data quality
• Download full text (pdf) of The National Swedish Lymphoma Register - a systematic validation of data quality

Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population-based study

Wästerlid, Tove; Dietrich, Caroline E.; Oksanen, Anna; Deleskog Spångberg, Linn et al.

Part of eJHaem, p. 516-526, 2024

• DOI for Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population-based study
• Download full text (pdf) of Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population-based study

A whole-body diffusion MRI normal atlas: development, evaluation and initial use

Sjöholm, Therese; Tarai, Sambit; Malmberg, Filip; Strand, Robin et al.

Part of Cancer Imaging, 2023

• DOI for A whole-body diffusion MRI normal atlas: development, evaluation and initial use
• Download full text (pdf) of A whole-body diffusion MRI normal atlas: development, evaluation and initial use

ADAR1-mediated RNA editing promotes B cell lymphomagenesis

Pecori, Riccardo; Ren, Weicheng; Pirmoradian, Mohammad; Binder, Marco et al.

Part of iScience, 2023

• DOI for ADAR1-mediated RNA editing promotes B cell lymphomagenesis
• Download full text (pdf) of ADAR1-mediated RNA editing promotes B cell lymphomagenesis

Next generation pan-cancer blood proteome profiling using proximity extension assay

Alvez, Maria Bueno; Edfors, Fredrik; von Feilitzen, Kalle; Zwahlen, Martin et al.

Part of Nature Communications, 2023

• DOI for Next generation pan-cancer blood proteome profiling using proximity extension assay
• Download full text (pdf) of Next generation pan-cancer blood proteome profiling using proximity extension assay

Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma-Possible Estrogen Effects

Huang, Dan; Berglund, Mattias; Damdimopoulos, Anastasios; Antonson, Per et al.

Part of Cancers, 2023

• DOI for Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma-Possible Estrogen Effects
• Download full text (pdf) of Sex- and Female Age-Dependent Differences in Gene Expression in Diffuse Large B-Cell Lymphoma-Possible Estrogen Effects

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients

Sarén, Tina; Ramachandran, Mohanraj; Gammelgård, Gustav; Lövgren, Tanja et al.

Part of Clinical Cancer Research, p. 4139-4152, 2023

• DOI for Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients
• Download full text (pdf) of Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma

Nikkarinen, Anna; Lokhande, Lavanya; Amini, Rose-Marie; Jerkeman, Mats et al.

Part of Blood Advances, p. 5304-5313, 2023

• DOI for Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma

Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2

Ginman, Beatrice; Pahnke, Simon; Freyhult, Eva; Hoffman, Tove et al.

Part of Acta Oncologica, p. 1707-1715, 2023

• DOI for Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2
• Download full text (pdf) of Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2

Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden

Weibull, Caroline E.; Wasterlid, Tove; Wahlin, Bjorn Engelbrekt; Andersson, Per-Ola et al.

Part of HemaSphere, 2023

• DOI for Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden
• Download full text (pdf) of Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden

Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

Apollonio, Benedetta; Spada, Filomena; Petrov, Nedyalko; Cozzetto, Domenico et al.

Part of Journal of Clinical Investigation, 2023

• DOI for Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
• Download full text (pdf) of Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

Advances in immune therapies in hematological malignancies

Mazzarella, Luca; Enblad, Gunilla; Olweus, Johanna; Malmberg, Karl-Johan et al.

Part of Journal of Internal Medicine, p. 205-220, 2022

• DOI for Advances in immune therapies in hematological malignancies
• Download full text (pdf) of Advances in immune therapies in hematological malignancies

Checkpoint CD47 expression in classical Hodgkin lymphoma

Gholiha, Alex Reza; Hollander, Peter; Löf, Liza; Glimelius, Ingrid et al.

Part of British Journal of Haematology, p. 580-589, 2022

• DOI for Checkpoint CD47 expression in classical Hodgkin lymphoma
• Download full text (pdf) of Checkpoint CD47 expression in classical Hodgkin lymphoma

COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients

Sundberg, Emil; Hoffman, Tove; Nilsson, Anna; Pahnke, Simon et al.

Part of Pediatric Blood & Cancer, 2022

• DOI for COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients
• Download full text (pdf) of COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients

Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis

Hellström, Vivan; Tufveson, Gunnar; Loskog, Angelica; Bengtsson, Mats et al.

Part of PLOS ONE, 2022

• DOI for Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
• Download full text (pdf) of Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis

Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue

Gholiha, Alex R.; Hollander, Peter; Löf, Liza; Larsson, Anders et al.

Part of Cancers, 2022

• DOI for Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
• Download full text (pdf) of Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Lagerlöf, Ingemar; Fohlin, Helena; Enblad, Gunilla; Glimelius, Bengt et al.

Part of Journal of Clinical Oncology, p. 1487-1496, 2022

• DOI for Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
• Download full text (pdf) of Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Noninvasive detection of any-stage cancer using free glycosaminoglycans

Bratulic, Sinisa; Limeta, Angelo; Dabestani, Saeed; Birgisson, Helgi et al.

Part of Proceedings of the National Academy of Sciences of the United States of America, 2022

• DOI for Noninvasive detection of any-stage cancer using free glycosaminoglycans
• Download full text (pdf) of Noninvasive detection of any-stage cancer using free glycosaminoglycans

Outcome in PCNSL patients and its association with PD-L1+leukocytes in the tumor microenvironment

Abdulla, Maysaa; Hollander, Peter; Lindskog, Cecilia; Sundström, Christer et al.

Part of Acta Oncologica, p. 824-829, 2022

• DOI for Outcome in PCNSL patients and its association with PD-L1+leukocytes in the tumor microenvironment

Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients

Harrysson, Sara; Eloranta, Sandra; Ekberg, Sara; Enblad, Gunilla et al.

Part of British Journal of Haematology, p. 267-277, 2022

• DOI for Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients
• Download full text (pdf) of Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients

Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes

Sköld, Camilla; Koliadi, Anthoula; Enblad, Gunilla; Stålberg, Karin et al.

Part of International Journal of Cancer, p. 773-781, 2022

• DOI for Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes
• Download full text (pdf) of Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Elsawy, Mahmoud; Chavez, Julio C.; Avivi, Irit; Larouche, Jean-Francois et al.

Part of Blood, p. 2248-2260, 2022

• DOI for Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

Sabaa, Amal Abu; Shen, Qiujin; Lennmyr, Emma; Enblad, Anna Pia et al.

Part of New Biotechnology, p. 21-29, 2022

• DOI for Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls
• Download full text (pdf) of Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

The dual role of CD70 in B‐cell lymphomagenesis

Nie, Man; Ren, Weicheng; Ye, Xiaofei; Berglund, Mattias et al.

Part of Clinical and Translational Medicine, 2022

• DOI for The dual role of CD70 in B‐cell lymphomagenesis
• Download full text (pdf) of The dual role of CD70 in B‐cell lymphomagenesis

Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology

Skaftason, Aron; Qu, Ying; Abdulla, Maysaa; Nordlund, Jessica et al.

Part of Genes, Chromosomes and Cancer, p. 27-36, 2022

• DOI for Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology
• Download full text (pdf) of Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology

Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Sjöholm, Therese; Korenyushkin, Alexander; Gammelgård, Gustav; Sarén, Tina et al.

Part of Cancer Imaging, 2022

• DOI for Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
• Download full text (pdf) of Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Sabaa, Amal Abu; Mörth, Charlott; Hasselblom, Sverker; Hedström, Gustaf et al.

Part of British Journal of Haematology, p. 906-914, 2021

• DOI for Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
• Download full text (pdf) of Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Wenthe, Jessica; Naseri, Sedigheh; Labani-Motlagh, Alireza; Enblad, Gunilla et al.

Part of Cancer Immunology and Immunotherapy, p. 2851-2865, 2021

• DOI for Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
• Download full text (pdf) of Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study

Ullgren, Helena; Camuto, Angela; Rosas, Sumy; Pahnke, Simon et al.

Part of Acta Oncologica, p. 1459-1465, 2021

• DOI for Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study
• Download full text (pdf) of Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study

High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?

Andersson, Anne; Enblad, Gunilla; Erlanson, Martin; Johansson, Ann-Sofie et al.

Part of Upsala Journal of Medical Sciences, 2021

• DOI for High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?
• Download full text (pdf) of High risk of cardiovascular side effects after treatment of Hodgkin's lymphoma - is there a need for intervention in long-term survivors?

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden

Harrysson, Sara; Eloranta, Sandra; Ekberg, Sara; Enblad, Gunilla et al.

Part of Blood Cancer Journal, 2021

• DOI for Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
• Download full text (pdf) of Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden

PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS

Abdulla, Maysaa; Alexsson, Andrei; Sundström, Christer; Ladenvall, Claes et al.

Part of Acta Oncologica, p. 531-538, 2021

• DOI for PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS
• Download full text (pdf) of PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS

Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Mörth, Charlott; Sabaa, Amal Abu; Freyhult, Eva; Christersson, Christina et al.

Part of Cardio-Oncology, 2021

• DOI for Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma

Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders

Kinch, Amelie; Baecklund, Eva; Molin, Daniel; Pauksen, Karlis et al.

Part of Acta Oncologica, p. 771-778, 2021

• DOI for Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders
• Download full text (pdf) of Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Vajavaara, Heli; Ekeblad, Frida; Holte, Harald; Jorgensen, Judit et al.

Part of Haematologica, p. 2502-2506, 2021

• DOI for Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma

Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma

Gholiha, Alex R.; Hollander, Peter; Glimelius, Ingrid; Hedström, Gustaf et al.

Part of Blood Advances, p. 1671-1681, 2021

• DOI for Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma

Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma

Mattsson Ulfstedt, Johan; Venge, Per; Holmgren, Sofia; Enblad, Gunilla et al.

Part of Upsala Journal of Medical Sciences, 2021

• DOI for Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma
• Download full text (pdf) of Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma

Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden

Sima, Andreea; Hollander, Peter; Baecklund, Eva; Smedby, Karin E. et al.

Part of British Journal of Haematology, p. 568-579, 2021

• DOI for Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden
• Download full text (pdf) of Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden

CD30 expression and survival in posttransplant lymphoproliferative disorders

Kinch, Amelie; Amini, Rose-Marie; Hollander, Peter; Molin, Daniel et al.

Part of Acta Oncologica, p. 673-680, 2020

• DOI for CD30 expression and survival in posttransplant lymphoproliferative disorders
• Download full text (pdf) of CD30 expression and survival in posttransplant lymphoproliferative disorders

Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome

Amini, Rose-Marie; Ljungström, Viktor; Abdulla, Maysaa; Cavelier, Lucia et al.

Part of American Journal of Hematology, 2020

• DOI for Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome
• Download full text (pdf) of Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome

Marginal zone lymphoma expression of histidine-rich glycoprotein correlates with improved survival

Persson Skare, Tor; Sjöberg, Elin; Berglund, Mattias; Smith, Ross O. et al.

Part of eJHaem, p. 199-207, 2020

• DOI for Marginal zone lymphoma expression of histidine-rich glycoprotein correlates with improved survival

No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Lagerlöf, Ingemar; Holte, Harald; Glimelius, Ingrid; Björkholm, Magnus et al.

Part of British Journal of Haematology, p. 685-691, 2020

• DOI for No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma

Wästerlid, Tove; Harrysson, Sara; Andersson, Therese M-L; Ekberg, Sara et al.

Part of American Journal of Hematology, p. 740-748, 2020

• DOI for Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
• Download full text (pdf) of Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma

Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma

Hollander, Peter; Ginman, Beatrice; Molin, Daniel; Enblad, Gunilla et al.

Part of Immunobiology, 2020

• DOI for Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma
• Download full text (pdf) of Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma

Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma

Abdulla, Maysaa; Guglielmo, Priscilla; Hollander, Peter; Åström, Gunnar et al.

Part of European Journal of Haematology, p. 207-213, 2020

• DOI for Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma
• Download full text (pdf) of Prognostic impact of abdominal lymph node involvement in diffuse large B-cell lymphoma

Relative and absolute cancer risks among Nordic kidney transplant recipients-a population-based study

Benoni, Henrik; Eloranta, Sandra; Dahle, Dag O.; Svensson, My H. S. et al.

Part of Transplant International, p. 1700-1710, 2020

• DOI for Relative and absolute cancer risks among Nordic kidney transplant recipients-a population-based study
• Download full text (pdf) of Relative and absolute cancer risks among Nordic kidney transplant recipients-a population-based study

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Crippa, Alessio; De Laere, Bram; Discacciati, Andrea; Larsson, Berit et al.

Part of Trials, 2020

• DOI for The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
• Download full text (pdf) of The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Niinivirta, Marjut; Georganaki, Maria; Enblad, Gunilla; Lindskog, Cecilia et al.

Part of BMC Cancer, 2020

• DOI for Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
• Download full text (pdf) of Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib

Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

Amini, Rose-Marie; Enblad, Gunilla; Hollander, Peter; Laszlo, S. et al.

Part of BMC Cancer, 2019

• DOI for Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
• Download full text (pdf) of Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Mörth, Charlott; Valachis, Antonios; Sabaa, Amal Abu; Marshall, Katharina et al.

Part of Acta Oncologica, p. 1170-1177, 2019

• DOI for Autoimmune disease in patients with diffuse large B-cell lymphoma: occurrence and impact on outcome

Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation

Kinch, Amelie; Sundström, Christer; Baecklund, Eva; Backlin, Carin et al.

Part of Leukemia and Lymphoma, p. 376-384, 2019

• DOI for Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation
• Download full text (pdf) of Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation

Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy

Pedersen, Mette A.; Gormsen, Lars C.; Kamper, Peter; Wassberg, Cecilia et al.

Part of British Journal of Haematology, p. 431-439, 2019

• DOI for Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy

High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms

Gholiha, Alex R.; Hollander, Peter; Hedström, Gustaf; Sundström, Christer et al.

Part of British Journal of Haematology, p. 192-201, 2019

• DOI for High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms

Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis

Hellbacher, Erik; Hjorton, Karin; Backlin, Carin; Enblad, Gunilla et al.

Part of Acta Oncologica, p. 1655-1659, 2019

• DOI for Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis

Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib

Niinivirta, Marjut; Enblad, Gunilla; Lindskog, Cecilia; Pontén, Fredrik et al.

Part of Journal of Cancer, p. 3224-3231, 2019

• DOI for Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib
• Download full text (pdf) of Tumoral pyruvate kinase L/R as a predictive marker for the treatment of renal cancer patients with sunitinib and sorafenib

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Gammelgård, Gustav; Wenthe, Jessica et al.

Part of Clinical Cancer Research, p. 6185-6194, 2018

• DOI for A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

Hollander, Peter; Rostgaard, Klaus; Ekström-Smedby, Karin; Molin, Daniel et al.

Part of European Journal of Haematology, p. 88-97, 2018

• DOI for An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
• Download full text (pdf) of An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Mörth, Charlott; Valachis, Antonis; Sabaa, Amal Abu; Molin, Daniel et al.

Part of Annals of Hematology, p. 2129-2135, 2018

• DOI for Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
• Download full text (pdf) of Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

Hollander, Peter; Amini, Rose-Marie; Ginman, Beatrice; Molin, Daniel et al.

Part of PLOS ONE, 2018

• DOI for Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
• Download full text (pdf) of Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients

Ednersson, Susanne Bram; Stenson, Martin; Stern, Mimmie; Enblad, Gunilla et al.

Part of British Journal of Haematology, p. 770-781, 2018

• DOI for Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients

Imiomics Using Whole-body FDG PET/MR in Staging and Treatment Response Evaluation of Non-Hodgkin Lymphoma Patients Treated With CAR-T Cells

Guglielmo, P.; Sjöholm, Therese; Enblad, Gunilla; Strand, Robin et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2018

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Harrysson, Sara; Eloranta, Sandra; Ekberg, Sara; Enblad, Gunilla et al.

Part of Blood, 2018

• DOI for Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013

Eloranta, Sandra; Brånvall, Elsa; Celsing, Fredrik; Papworth, Karin et al.

Part of European Journal of Haematology, p. 61-68, 2018

• DOI for Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

Ekberg, Sara; Jerkeman, Mats; Andersson, Per-Ola; Enblad, Gunilla et al.

Part of American Journal of Hematology, p. 1020-1028, 2018

• DOI for Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Smedby, Karin Ekstrom; Harrysson, Sara; Andersson, Per-Ola; Enblad, Gunilla et al.

Part of Blood, 2018

• DOI for Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study

Wasterlid, T.; Biccler, J. L.; Brown, P. N.; Bogsted, M. et al.

Part of Annals of Oncology, p. 1882-1883, 2018

• DOI for Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study

U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Glimelius, Bengt; Melin, Beatrice; Enblad, Gunilla; Alafuzoff, Irina et al.

Part of Acta Oncologica, p. 187-194, 2018

• DOI for U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.
• Download full text (pdf) of U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden.

Core needle biopsies for the diagnosis of diffuse large B-cell lymphoma - a great concern for research

Abdulla, Maysaa; Laszlo, Sofia; Triumf, Johanna; Hedström, Gustaf et al.

Part of Acta Oncologica, p. 106-109, 2017

• DOI for Core needle biopsies for the diagnosis of diffuse large B-cell lymphoma - a great concern for research

Does the omission of vincristine affect outcome and survival in patients with diffuse large B-cell lymphoma?

Mörth, Charlott; Valachis, Antonis; Abu Sabaa, Amal; Hedström, Gustaf et al.

Part of Annals of Oncology, 2017

Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

Hellström, Vivan; Tufveson, Gunnar; Wallgren, AnnaCarin; Loskog, Angelica et al.

Part of American Journal of Transplantation, p. 472-472, 2017

• DOI for Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

Estrogen receptor beta 1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker

Hasni, Muhammad Sharif; Berglund, Mattias; Yakimchuk, Konstantin; Guan, Jiyu et al.

Part of Leukemia and Lymphoma, p. 418-427, 2017

• DOI for Estrogen receptor beta 1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker

Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma

Delforoush, Maryam; Berglund, Mattias; Edqvist, Per-Henrik; Sundström, Christer et al.

Part of European Journal of Haematology, p. 52-56, 2017

• DOI for Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma

High posttransplant cancer incidence in renal transplanted patients with pretransplant cancer

Hellström, Vivan; Lorant, Tomas; Döhler, Bernd; Tufveson, Gunnar et al.

Part of Transplantation, p. 1295-1302, 2017

• DOI for High posttransplant cancer incidence in renal transplanted patients with pretransplant cancer

High proportions of PD-1⁺ and PD-L1⁺ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Hollander, Peter; Kamper, Peter; Smedby, Karin Ekstrom; Enblad, Gunilla et al.

Part of Blood Advances, p. 1427-1439, 2017

• DOI for High proportions of PD-1⁺ and PD-L1⁺ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

Immunological biomarkers correlate to survival in CAR19-treated patients

Lövgren, Tanja; Wenthe, Jessica; Karlsson, S. C. Hannah; Gammelgård, Gustav et al.

Part of Scandinavian Journal of Immunology, p. 337-337, 2017

Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing

Enblad, Gunilla; Martinsson, Gustaf; Baecklund, Eva; Hesselager, Göran et al.

Part of Acta Oncologica, p. 599-607, 2017

• DOI for Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing

Risk Factors for De Novo Squamous Cell Carcinoma Development in Renal Transplant Recipients with a Previous Squamous Cell Carcinoma.

Hellström, Vivan; Enström, Ylva; Enblad, Gunilla; Tufveson, Gunnar et al.

Part of Acta Dermato-Venereologica, p. 751-753, 2017

• DOI for Risk Factors for De Novo Squamous Cell Carcinoma Development in Renal Transplant Recipients with a Previous Squamous Cell Carcinoma.

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Niinivirta, Marjut; Enblad, Gunilla; Edqvist, Per-Henrik D; Pontén, Fredrik et al.

Part of Journal of Cancer, p. 3975-3983, 2017

• DOI for Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
• Download full text (pdf) of Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib

Niinivirta, Marjut; Enblad, Gunilla; Edqvist, Per-Henrik; Pontén, Fredrik et al.

Part of Journal of Cancer Research and Clinical Oncology, p. 961-970, 2017

• DOI for Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
• Download full text (pdf) of Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib

A Clinical Trial Using Third Generation CD19 Targeting CAR T Cells for Relapsed Lymphoma and Leukemia

Enblad, Gunilla; Karlsson, Hannah; Wenthe, Jessica; Wikström, Kristina I. et al.

Part of Molecular Therapy, 2016

A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients

Abdulla, Maysaa; Laszlo, Sofia; Triumf, Johanna; Hedström, Gustaf et al.

Part of Acta Oncologica, p. 1126-1131, 2016

• DOI for A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma

Johnson, Peter; Federico, Massimo; Kirkwood, Amy; Fossa, Alexander et al.

Part of New England Journal of Medicine, p. 2419-2429, 2016

• DOI for Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma

CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial

Enblad, Gunilla; Karlsson, Hannah; Wikström, Kristina I.; Essand, Magnus et al.

Part of CANCER IMMUNOLOGY RESEARCH, 2016

• DOI for CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial

Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

Melén, Christopher M.; Enblad, Gunilla; Sonnevi, Kristina; Junlen, Henna Riikka et al.

Part of British Journal of Haematology, p. 614-622, 2016

• DOI for Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

Diffuse Large B Cell Lymphoma Cell Line U2946: Model for MCL1 Inhibitor Testing

Quentmeier, Hilmar; Drexler, Hans G.; Hauer, Vivien; MacLeod, Roderick A. F. et al.

Part of PLOS ONE, 2016

• DOI for Diffuse Large B Cell Lymphoma Cell Line U2946: Model for MCL1 Inhibitor Testing
• Download full text (pdf) of Diffuse Large B Cell Lymphoma Cell Line U2946: Model for MCL1 Inhibitor Testing

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Mansouri, Larry; Noerenberg, Daniel; Young, Emma; Mylonas, Elena et al.

Part of Blood, p. 2666-2670, 2016

• DOI for Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Georgiou, Konstantinos; Chen, Longyun; Berglund, Mattias; Ren, Weicheng et al.

Part of Blood, p. 3026-3034, 2016

• DOI for Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

High Expression Of Programmed Cell Death Receptor 1 In The Tumor Microenvironment Is Associated With Inferior Event Free Survival In Classical Hodgkin Lymphoma

Hollander, Peter; Kamper, P.; Smedby, K. E.; Enblad, Gunilla et al.

Part of Haematologica, p. 1-2, 2016

In vitro and in vivo activity of melflufen (J1) in lymphoma

Delforoush, Maryam; Strese, Sara; Wickström, Malin; Larsson, Rolf et al.

Part of BMC Cancer, 2016

• DOI for In vitro and in vivo activity of melflufen (J1) in lymphoma

Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

Hellström, Vivan; Enström, Ylva; von Zur-Mühlen, Bengt; Hagberg, Hans et al.

Part of Acta Oncologica, p. 774-781, 2016

• DOI for Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment

Hollander, Peter; Rostgaard, K.; Smedby, K. E.; Molin, Daniel et al.

Part of Haematologica, p. 3-3, 2016

The Importance Of Bone Marrow 18F-Fdg Uptake And Focal Skeletal Lesions On Survival In Patients With Newly Diagnosed Hodgkin Lymphoma

Pedersen, M. A.; Gormsen, L. C.; Kamper, P.; d'Amore, A. et al.

Part of Haematologica, p. 42-42, 2016

The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children

Englund, Annika; Molin, Daniel; Enblad, Gunilla; Karlén, Jonas et al.

Part of European Journal of Haematology, p. 430-438, 2016

• DOI for The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children
• Download full text (pdf) of The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children

CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

Enblad, Gunilla; Karlsson, Hannah; Loskog, Angelica S. I.

Part of Human Gene Therapy, p. 498-505, 2015

• DOI for CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma

Elevated Post-Transplant Cancer Incidence And Reduced Survival In Patients With Pretransplant Tumors

Hellström, Vivan; Lorant, Tomas; Dohler, Bernd; Tufveson, Gunnar et al.

Part of Transplant International, p. 183-184, 2015

Expression of Intratumoral Forkhead Box Protein 3 in Posttransplant Lymphoproliferative Disorders: Clinical Features and Survival Outcomes

Berglund, David; Kinch, Amelie; Edman, Elin; Backlin, Carin et al.

Part of Transplantation, p. 1036-1042, 2015

• DOI for Expression of Intratumoral Forkhead Box Protein 3 in Posttransplant Lymphoproliferative Disorders: Clinical Features and Survival Outcomes